Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$112.24 +0.8%	$106.47	$72.21 ▼ $139.13	$5.48B	0.46	667,390 shs	512,298 shs
INSM Insmed	$104.17 -0.4%	$86.18	$60.40 ▼ $106.83	$19.84B	0.9	2.30 million shs	2.00 million shs
JAZZ Jazz Pharmaceuticals	$114.86 -1.1%	$108.83	$95.49 ▼ $148.06	$7.02B	0.32	833,093 shs	886,533 shs
SMMT Summit Therapeutics	$27.63 -2.3%	$22.77	$8.71 ▼ $36.91	$21.00B	-1.01	3.75 million shs	3.08 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+0.83%	+1.36%	+10.47%	+7.45%	+34.03%
INSM Insmed	-0.40%	+7.77%	+3.88%	+43.63%	+37.90%
JAZZ Jazz Pharmaceuticals	-1.05%	+2.12%	+7.30%	+11.75%	+6.34%
SMMT Summit Therapeutics	-2.26%	+6.76%	+39.19%	+12.27%	+196.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.6968 of 5 stars	4.5	1.0	4.5	2.1	4.2	0.6
INSM Insmed	3.8718 of 5 stars	2.5	4.0	4.3	2.2	1.7	0.6
JAZZ Jazz Pharmaceuticals	4.8195 of 5 stars	4.5	1.0	4.0	1.4	3.3	2.5
SMMT Summit Therapeutics	2.8746 of 5 stars	4.4	3.0	0.0	1.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	53.54% Upside
INSM Insmed	3.00	Buy	$108.47	4.12% Upside
JAZZ Jazz Pharmaceuticals	2.93	Moderate Buy	$181.71	58.21% Upside
SMMT Summit Therapeutics	2.79	Moderate Buy	$34.67	25.47% Upside

Current Analyst Ratings Breakdown

Latest AXSM, JAZZ, INSM, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$102.00 ➝ $108.00
7/15/2025	JAZZ Jazz Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$152.00
7/8/2025	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $111.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
7/1/2025	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$44.00
7/1/2025	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/11/2025	INSM Insmed	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $112.00
6/11/2025	INSM Insmed	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
6/11/2025	INSM Insmed	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$99.00 ➝ $106.00
6/11/2025	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$90.00 ➝ $102.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	14.33	N/A	N/A	$1.18 per share	95.12
INSM Insmed	$363.71M	54.33	N/A	N/A	$1.60 per share	65.11
JAZZ Jazz Pharmaceuticals	$4.07B	1.71	$30.07 per share	3.82	$67.72 per share	1.70
SMMT Summit Therapeutics	$700K	29,314.25	N/A	N/A	$0.53 per share	52.13

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	39.80	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
INSM Insmed	-$913.77M	-$5.95	N/A	N/A	N/A	-265.93%	-446.98%	-52.70%	8/6/2025 (Estimated)
JAZZ Jazz Pharmaceuticals	$560.12M	$7.50	15.31	6.14	5.80	11.86%	26.62%	9.14%	7/30/2025 (Estimated)
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)

Latest AXSM, JAZZ, INSM, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	INSM Insmed	-$1.31	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	SMMT Summit Therapeutics	-$0.10	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
7/30/2025	Q2 2025	JAZZ Jazz Pharmaceuticals	-$5.61	N/A	N/A	N/A	$1.05 billion	N/A
5/8/2025	Q1 2025	INSM Insmed	-$1.36	-$1.42	-$0.06	-$1.42	$91.63 million	$92.82 million
5/6/2025	Q1 2025	JAZZ Jazz Pharmaceuticals	$4.65	$1.68	-$2.97	-$1.52	$984.16 million	$897.84 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
INSM Insmed	11.38	5.86	5.44
JAZZ Jazz Pharmaceuticals	1.28	3.38	2.97
SMMT Summit Therapeutics	N/A	10.63	10.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
INSM Insmed	N/A
JAZZ Jazz Pharmaceuticals	89.14%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
INSM Insmed	3.00%
JAZZ Jazz Pharmaceuticals	4.30%
SMMT Summit Therapeutics	84.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
INSM Insmed	1,271	189.71 million	184.02 million	Optionable
JAZZ Jazz Pharmaceuticals	2,800	60.51 million	57.91 million	Optionable
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable

AXSM, JAZZ, INSM, and SMMT Headlines

Recent News About These Companies

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 17 at 10:53 AM | tmcnet.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 17 at 10:00 AM | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Shares Up 9% - Still a Buy?

July 16 at 1:00 PM | marketbeat.com

Florida Financial Advisors LLC Purchases Shares of 12,945 Summit Therapeutics PLC (NASDAQ:SMMT)

July 15 at 5:50 AM | marketbeat.com

SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm

July 14, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 12, 2025 | prnewswire.com

12,025 Shares in Summit Therapeutics PLC (NASDAQ:SMMT) Purchased by U.S. Capital Wealth Advisors LLC

July 12, 2025 | marketbeat.com

Summit Therapeutics Inc. (SMMT) Stock Price Today - WSJ

July 10, 2025 | wsj.com

Summit Therapeutics (NASDAQ:SMMT) Trading 7.6% Higher - Here's Why

July 9, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMT

July 7, 2025 | prnewswire.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Down - Here's Why

July 7, 2025 | marketbeat.com

SMMT Stock Gains on Rumored Licensing Talks With AstraZeneca

July 7, 2025 | zacks.com

Summit Therapeutics Inc. (SMMT) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

2 Soaring Stocks With More Upside Potential to Buy and Hold

July 4, 2025 | fool.com

AstraZeneca in talks with Summit for over $15 billion license deal

July 4, 2025 | thepharmaletter.comT

Summit, AstraZeneca in talks over $15 billion partnership deal, Bloomberg News reports

July 3, 2025 | msn.com

Summit Therapeutics Shares Climb Amid Rumored $15B Deal Talks with AstraZeneca

July 3, 2025 | msn.com

Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

July 3, 2025 | msn.com

Why Summit Therapeutics Stock Soared 8% Higher Today

July 3, 2025 | fool.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 4.3% - Should You Sell?

July 3, 2025 | marketbeat.com

Summit Therapeutics Target of Unusually High Options Trading (NASDAQ:SMMT)

July 3, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Russell Rebalance: 3 Stocks Ready to Move Higher
By Chris Markoch | June 20, 2025
View Russell Rebalance: 3 Stocks Ready to Move Higher

AXSM, JAZZ, INSM, and SMMT Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$112.24 +0.92 (+0.83%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$112.00 -0.23 (-0.21%)

As of 07/17/2025 07:56 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Insmed NASDAQ:INSM

$104.17 -0.42 (-0.40%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$106.32 +2.15 (+2.07%)

As of 07/17/2025 07:08 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Jazz Pharmaceuticals NASDAQ:JAZZ

$114.86 -1.22 (-1.05%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$114.91 +0.05 (+0.04%)

As of 07/17/2025 06:00 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Summit Therapeutics NASDAQ:SMMT

$27.63 -0.64 (-2.26%)

Closing price 07/17/2025 04:00 PM Eastern

Extended Trading

$27.66 +0.04 (+0.13%)

As of 07/17/2025 07:53 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time